Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Field Trip Health Ltd. (FTRP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.1400-0.1500 (-3.50%)
At close: 1:00PM EST
4.1400 0.00 (0.00%)
After hours: 04:53PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Hammer

Hammer

Previous Close4.2900
Open4.2600
Bid4.0800 x 1300
Ask4.1300 x 800
Day's Range4.0000 - 4.3100
52 Week Range2.5000 - 7.7090
Volume88,170
Avg. Volume129,479
Market Cap239.255M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.6670
Earnings DateFeb 14, 2022 - Feb 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.91
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for FTRP

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Field Trip Health Ltd.
    BLL: Lowering target price to $104.00BALL CORP has an Investment Rating of BUY; a target price of $104.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    23 days agoArgus Research
View more
  • GlobeNewswire

    Field Trip Health Ltd. Reports Second Fiscal Quarter 2022 Financial Results and Provides Business Update

    Announced plans to advance FT-104, its novel psychedelic compound, to clinic for Treatment-Resistant Depression and Postpartum Depression as the lead indications.Initiated a new pipeline research program focused on discovering novel psychedelics with a reduced cardiovascular risk profile compared to classic psychedelics (the “FT-200 Group”) and filed a provisional patent in connection to the composition of matter for the first molecule identified in the FT-200 Group.Continued to invest in best-i

  • GlobeNewswire

    Field Trip Health Ltd. to Participate in Upcoming Conferences in November 2021

    TORONTO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that during the month of November management will attend the Microdose Wonderland: Miami Conference and present at the Stifel 2021 Virtual Healthcare Conference and the Jefferies London Healthcare Conference. Wonderland: Miami Conference Field Trip’s Co-founder and Executive Chairman, Ronan L

  • GlobeNewswire

    Field Trip Health Ltd. Schedules Second Fiscal Quarter 2022 Financial Results Conference Call for Tuesday, November 16, 2021 at 8:30 AM ET

    TORONTO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for the fiscal second quarter ended September 30, 2021, after market close on Monday, November 15, 2021. The Company will conduct a conference call and webcast to discuss its results the following morning, Tuesday, November 16 at 8:30 am ET. To acces

Advertisement
Advertisement